Medically reviewed by Anju Goel, MD Many peptide medications like glucagon-like peptide-1 (GLP-1) receptor agonists were ...

GLP-1 receptor agonists are transforming obesity treatment, but manufacturing challenges must be addressed to meet rising ...

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced ...

a glucagon-like peptide-1 (GLP-1)/gastric inhibitory polypeptide (GIP), to treat obesity. The final output collection and quality control will be completed soon, with top-line data anticipated ...